Revance Therapeutics Executive and Leadership Team

Nadeem Moiz, the Chief Executive Officer at Revance Therapeutics, directs the company's overall strategic vision and operational execution. This leadership role involves guiding the development, manufacturing, and commercialization of novel botulinum toxin products, ensuring alignment with market needs and scientific advancement. Moiz oversees the progression of key drug candidates like DaxibotulinumtoxinA for injection through clinical trials, targeting both aesthetic and therapeutic indications such as glabellar lines, cervical dystonia, and plantar fasciitis. The Chief Executive Officer's responsibilities extend to fostering innovation and ensuring the company's long-term growth trajectory within the competitive biotechnology landscape. Nadeem Moiz drives the company's mission to redefine patient care through cutting-edge treatments.

Scott Leffler, the Chief Financial Officer at Revance Therapeutics, manages the company's financial strategy, planning, and reporting. This critical executive role encompasses overseeing all fiscal operations, including budgeting, forecasting, and capital allocation to support the development and commercialization of the company's product pipeline. Leffler ensures robust financial controls are in place to manage the significant investments required for clinical trials and manufacturing scale-up of novel botulinum toxin products. The Chief Financial Officer's guidance is essential for maintaining investor confidence and securing the necessary funding for ongoing research and market expansion. Scott Leffler drives financial discipline to support Revance Therapeutics' long-term objectives.

Nicholas Crowe, the Chief Operating Officer at Revance Therapeutics, directs the company's operational efficiency and execution across all business functions. This leadership position involves optimizing manufacturing processes, supply chain management, and the overall operational readiness for commercial product launches. Crowe ensures that the development and production of novel botulinum toxin products, including DaxibotulinumtoxinA for injection and topical gel, adhere to stringent quality and regulatory standards. The Chief Operating Officer's focus on operational excellence supports the seamless progression of clinical trials and the scalable delivery of therapeutic and aesthetic solutions to the market. Nicholas Crowe enhances the company's capacity to meet market demand effectively.

Satish Kalala, the Chief Technology Officer at Revance Therapeutics, architects the company's technological infrastructure and innovation pipeline. This executive function involves overseeing the research and development of novel drug delivery systems and manufacturing processes, particularly for botulinum toxin products. Kalala's purview includes advancing the preclinical development of DaxibotulinumtoxinA topical gel and ensuring the technological integrity of ongoing clinical trials for DaxibotulinumtoxinA for injection. The Chief Technology Officer's strategic direction supports the company's commitment to scientific excellence and the efficient translation of research into viable therapeutic and aesthetic solutions. Satish Kalala ensures that technological capabilities consistently meet the evolving demands of product development and commercialization.

Matthew Argano, the Chief Human Resources Officer at Revance Therapeutics, leads the strategic development and implementation of human capital initiatives. This executive function focuses on cultivating a high-performance culture, attracting and retaining top talent, and fostering employee engagement across the organization. Argano oversees talent acquisition, organizational development, and compensation and benefits programs, ensuring that the workforce is equipped to support the company's mission in developing and commercializing innovative botulinum toxin products. The Chief Human Resources Officer's efforts are vital for building a robust team capable of navigating the complexities of the biotechnology sector and driving scientific breakthroughs. Matthew Argano champions the people-centric strategies essential for Revance Therapeutics' success.

Steven Kreider, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics at Revance Therapeutics, spearheads the commercial strategy and revenue generation for the company's product portfolio. This senior leadership role involves driving sales performance, market penetration, and business development initiatives within both the aesthetic and therapeutic sectors. Kreider's focus is on maximizing the commercial success of novel botulinum toxin products, including DaxibotulinumtoxinA for injection and its associated indications. The Chief Revenue Officer's expertise is crucial in building strong customer relationships, expanding market access, and achieving ambitious revenue targets. Steven Kreider leads the commercial teams to deliver significant market impact and growth.

Kira Schwartz, the Chief Legal Officer at Revance Therapeutics, provides strategic legal counsel and oversees all legal affairs for the company. This executive position involves managing corporate governance, intellectual property, regulatory compliance, and litigation matters related to the development and commercialization of novel biotechnology products. Schwartz ensures that Revance Therapeutics operates within all applicable legal frameworks, safeguarding the company's interests and assets. The Chief Legal Officer's role is integral to navigating the complex regulatory landscape inherent in pharmaceutical development and commercialization, particularly for products like DaxibotulinumtoxinA. Kira Schwartz provides essential legal oversight to support the company's strategic objectives and mitigate risk.